
Artificial intelligence (AI) and computational methods are a powerful tool for antibody discovery and engineering. Despite historical prevalence in small molecule-related applications, AI is progressively being utilized in the discovery and advancement of therapeutic antibodies, backed by the surge in computational power and innovative algorithms, with an increasing amount of data obtained through next-generation sequencing and related drug modalities such as VHH antibodies.1
The main uses of these approaches in antibody research involve2:
Building antibody databases, e.g. for antibody engineering
Target discovery and validation
Development assessment and activity improvements
De novo antibody design
In combination with other tools (e.g. bioinformatics and X-ray crystallography protein structure analysis)
These computational methods can provide much more cost-efficient and rapid turnaround time compared to the laborious experimental methods that are common in antibody discovery. Escalating costs are often a significant impediment to the advancement of drug discovery.
At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
Norman, R. A., Ambrosetti, F., Bonvin, A. M., Colwell, L. J., Kelm, S., Kumar, S., & Krawczyk, K. (2020). Computational approaches to therapeutic antibody design: Established methods and emerging trends. Briefings in Bioinformatics, 21(5), 1549-1567. https://academic.oup.com/bib/article/21/5/1549/5581643
Kim, J., McFee, M., Fang, Q., Abdin, O., & Kim, P. M. (2023). Computational and artificial intelligence-based methods for antibody development. Trends in Pharmacological Sciences, 44(3), 175–189. https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(22)00279-6
In this article, we explore the major trends shaping the future of targeted canc……
Site-specific conjugation limits payload attachment to defined positions on the ……
Affinity maturation can improve binding to the intended target, but it can also ……
ADC development is no longer limited to the antibody-linker-toxin model. The fie……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



